(NRSN)

0.00

0.00 (0.00%)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

(NRSN)

0.00

0.00 (0.00%)

24.03.2026

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

18.03.2026

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

16.03.2026

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional decline, reduced risk of ALS-related complications, and modulation of disease-relevant biomarkers CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

09.03.2026

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

18.02.2026

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

09.02.2026

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

21.01.2026

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Videolar

No Data

There is no data to display

Press-relizlar